Clover Health Investments, Corp.
NASDAQ:CLOVMedical - Healthcare Plans
+$0.17 today
- Market cap
- $2.21B
- Beta
- 2.48
- P/E (TTM)
- -45.6
- EPS (TTM)
- -$0.11
Volume 8.05M
Average 7.31M
CLOV Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Clover Health Investments, Corp.NASDAQ: CLOV
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $564K rose 43.1% year over year, ahead of the +23.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 9.5% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.
Context
- Depreciation & amortization amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +43.1% holds above the trailing-twelve-month pace of +23.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.69M USD
- Year-over-year change
- +26.7%
- 4-year CAGR
- +7.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.69M | +26.7% |
| FY2024 | 2024-12-31 | 1.33M | -47.0% |
| FY2023 | 2023-12-31 | 2.51M | +111.4% |
| FY2022 | 2022-12-31 | 1.19M | -4.7% |
| FY2021 | 2021-12-31 | 1.25M | — |
Depreciation & Amortization vs competitors
How CLOV compares with its peers on the latest reported figures
- CLOV's LTM Jun 2026 depreciation & amortization of $1.91M is the smallest of the 7 companies compared; the peer median is $1B.
- Its year-over-year change of +23.5% is the highest of 7, against a peer median of -1.6%.
- Depreciation & amortization amounts to 0.1% of revenue for CLOV, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.52B | -2.4% | +2.9% | 1.1% | |
| LTM Sep 2026 | $2.89B | +7.2% | -1.9% | 1.0% | |
| LTM Jun 2026 | $1.25B | -0.8% | -6.4% | 0.6% | |
| LTM Sep 2026 | $763M | -12.3% | -0.8% | 0.5% | |
| LTM Mar 2026 | $30.72M | +7.2% | +21.8% | 0.7% | |
| LTM Jun 2026 | $28.24M | -7.2% | +23.6% | 0.2% | |
| LTM Jun 2026 | $1.91M | +23.5% | +12.4% | 0.1% | |
| Peer median (excluding CLOV) | $1B | -1.6% | +1.0% | 0.7% | |
Competitors are the stored peer set for CLOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (587.76M) | (339.57M) | (213.36M) | (43.01M) | (85.55M) |
| Depreciation & Amortization | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M |
| Deferred Income Tax | (66.09M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 163.72M | 164.31M | 140.93M | 114.33M | 103.66M |
| Change in Working Capital | 192.67M | (2.36M) | (55.43M) | 12.86M | (84.2M) |
| Accounts Receivables | (9.39M) | (8.03M) | 0 | (6.55M) | (65.95M) |
| Inventory | 9.39M | 0 | 0 | 0 | 0 |
| Accounts Payables | 5.31M | 7.64M | 4.74M | (2.62M) | 1.65M |
| Other Working Capital | 187.37M | (1.97M) | (60.17M) | 22.03M | (19.9M) |
| Other Non-Cash Items | 13.88M | (27.49M) | 9.48M | (50.66M) | (2.53M) |
| Operating Cash Flow | (282.33M) | (203.93M) | (115.87M) | 34.85M | (66.93M) |
| Capital Expenditures | (723K) | (4.47M) | (584K) | (1.56M) | (2.04M) |
| Acquisitions (Net) | 434.72M | (16.2M) | 0 | 0 | 0 |
| Purchases of Investments | (876.25M) | (369.65M) | (175.57M) | (201.24M) | (205.1M) |
| Sales of Investments | 441.53M | 485.45M | 316.16M | 203.36M | 211.22M |
| Other Investing Activities | (434.72M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (435.45M) | 95.13M | 140.01M | 565K | 4.08M |
| Debt Repayment | (30.93M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 289.92M | 1.4M | 1.15M | 902K | 1.81M |
| Common Stock Repurchased | (147K) | (6.36M) | (6.22M) | (18.26M) | (55.2M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 666.55M | 0 | (28.79M) | 0 | 0 |
| Financing Cash Flow | 925.39M | (4.96M) | (33.86M) | (17.36M) | (53.38M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 207.62M | (113.76M) | (9.72M) | 18.05M | (116.24M) |
| Free Cash Flow | (283.05M) | (208.39M) | (116.46M) | 33.29M | (68.98M) |
Clover Health Investments, Corp.
NASDAQ:CLOV
Intrinsic Alpha fair value
Locked
Current Price
$4.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.